1. Please check and comment entries here.
Table of Contents

    Topic review

    Mast Cells

    View times: 220
    Submitted by: Gaetano Gallo


    Mast Cells (MCs), from the German mast meaning well-fed, were first described by Paul Ehrlich in 1878 based on the unique color-changing granules within these cells. In fact, MCs are easily recognizable with characteristic toluidine blue-positive granules in the cytoplasm. Their granules contain several elements, such as histamine, serotonin, heparin, proteases (chymase, tryptase, carboxypeptidase), cytokines and other growth factors (vascular endothelial growth factor, VEGF; fibroblast growth factor-2, FGF-2). Tryptases and chymases are considered MC-specific proteases, but the granules also contain some non-specific enzymes, such as metalloproteinase-9.

    1. Introduction

    MCs are round or elongated in shape and have diameters ranging from 8 to 20 μm and are bone marrow-derived leukocytes (CD34+) that are not present in avascular tissue[1]; they play a key role in the homeostasis of wound healing as well as in both innate and adaptive immunity. These processes are closely controlled by microenvironmental stimuli, leading to the development of different subtypes.

    In contrast to other cells, they leave the bone marrow from an immature non-granulated precursor[2] that circulates in the blood and becomes mature under the influence of growth factors such as stem cell factor (SCF) and the ligand for c-kit receptor (CD117). There are two distinct types of MC: connective tissue and mucosa. Usually, the latter represent 2% of mucosal cells in the healthy gut, but this number can increase in response to different stimuli.

    2. Mast Cells (MCs) and Tumor

    In 1891, an MC was identified by Westphal at the tumor periphery[3]. Since then, several studies have hypothesized the role of MCs in tumor development and progression[4], correlating their infiltration with a poor prognosis in gastrointestinal tumors[5][6][7][8], including CRC[9].

    In fact, tumor cells produce SCF, which is the main chemoattractant and survival factor for MCs, with the consequent activation of the c-Kit pathway[10][11][12]. Thus, they are recruited in the initial step of tumorigenesis, promoting the angiogenic switch[13] through the release of anti- or pro-angiogenetic factors based on stimuli received by the TME that can regulate MC and contribute to ECM remodeling, which is crucial for tumor progression, invasion and metastasis. In particular, interleukin (IL)-1, IL-4, IL-6 or Tumor Necrosis Factor alpha (TNF-α) can act as antitumoral factors, whereas FGF-2, VEGF, Matrix Metalloproteinases (MMP-9), tryptase, chymase, IL-8 and IL-10 promote tumorigenesis[14].

    Angiogenesis is an indicator of tumor aggressiveness and is essential for tumor spread, providing a vascular route[15]. During tumorigenesis, cancer cells face a shortage of supply of nutrients, which leads to the creation of a hypoxic and acidotic TME. Consequently, angiogenesis can help to restore a sufficient blood supply through the formation of new vessels. In this context, the role of endothelial cells (ECs) is crucial for the ability to suppress recruitment and activity of circulating T cells. Under hypoxic conditions, MCs release IL-6, VEGF-A and C-X-C motif ligand 8 (CXCL8), which promote epithelial-to-mesenchymal transition (EMT) in cancer cells[12].

    In this respect, according to Engel et al.[16], the number of microvessels is an important predictor of CRC recurrence and time to recurrence. These results were confirmed by Frank et al.[17] in 105 patients with CRC. Furthermore, MCs regulate lymphangiogenesis by releasing VEGF-C and VEGF-D[18][19]. Marech et al.[11] accurately described the biological and translational significance of MCs density in CRC, pointing out the close relationship between MCs and angiogenesis-mediated tumor progression (Figure 1).

    Figure 1. The close relationship between mast cells (MCs) and tumor progression angiogenesis-mediated. Reproduced with permission from Marech et al. [11].

    Tryptases are tetrameric neutral serine proteases; they are most abundant in MC secretory granules and are the main stimulating factors of neovascularization and EC proliferation[20].

    Two main types of MC tryptases exist: alfa and beta. Alpha-tryptases are stored in the granules of MCs, whereas beta-tryptases circulate in the blood as inactive proenzymes and are the major constituents of secretory granules in humans[21].

    Positive MCs tryptase expression has a negative effect on prognosis[22], and its density is associated with advanced tumor parameters and aggressive behavior, i.e., tumor size and lymph node metastasis in solid tumors.

    Tryptases are agonists of protease-activated receptor-2 (PAR-2), which belongs to the superfamily of G-protein-coupled receptors and is expressed on EC and epithelial cells. Once activated, PAR-2 induces cell proliferation, releasing angiogenic factors and granulocyte-macrophage colony-stimulating factor (GM-CSF).

    Histamine is one of the factors released by MCs, and it exerts its functions through four receptors (H1–H4) and has been involved in CRC development. In fact, patients treated with cimetidine (histamine antagonist) reported a significant symptomatic improvement as well as a survival benefit[23][24]. However, the results regarding the role of histamine are still controversial.

    High MC density is correlated with advanced stage, tumor progression and poor outcome in CRC[8][25]. Targeted MC therapy is under development, and only a few studies have tried to investigate this issue[26]. Among these studies, tyrosine kinase inhibitors (imatinib and masitinib) for c-Kit receptor and MC tryptase inhibitors (gabexate mesylate, nafamostat mesylate and tranilast) are the best known and most studied[27][28].

    Interestingly, in a series of 61 consecutive patients with CRC, the correlation between serum tryptase levels before surgery and tumor-mediated angiogenesis was demonstrated. The authors concluded that elevated levels of serum tryptases after surgery could be indicative of residual tumor tissue or unknown metastases[9] [33]. Ammendola et al.[28] summarized the main in vivo/in vitro strategies of targeted MC therapy in solid tumors and their metastasis. A better understanding of the complex relationships between the whole angiogenesis signaling pathway and MC can represent the future of therapy aimed at arresting tumor growth in gastrointestinal cancer.

    This entry is adapted from 10.3390/jcm9092852


    1. Rae Silver; Ann-Judith Silverman; Ljubiša Vitković; Israel I Lederhendler; Mast cells in the brain: evidence and functional significance. Trends in Neurosciences 1996, 19, 25-31, 10.1016/0166-2236(96)81863-7.
    2. Yoshimichi Okayama; Toshiaki Kawakami; Development, Migration, and Survival of Mast Cells. Immunologic Research 2006, 34, 97-116, 10.1385/ir:34:2:97.
    3. Westphal, E. Uber Mastzellen. In Farbenanalytische Untersuchungen; Ehrlich, E., Ed.; Hirschwald: Berlin, Germany, 1891; pp. 17–41
    4. Pio Conti; Maria L. Castellani; Durasamy Kempuraj; Vincenzo Salini; Jacopo Vecchiet; Stefano Tetè; Filiberto Mastrangelo; Alessandro Perrella; Maria Anna De Lutiis; Michael Tagen; et al. Role of mast cells in tumor growth.. Annals of clinical and laboratory science 2007, 37, 315–322, .
    5. Acikalin, M.F.; Oner, U.; Topcu, I.; Yasar, B.; Kiper, H.; Colak, E. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig. Liver Dis. 2005, 37, 162–169.
    6. Melillo, R.M.; Guarino, V.; Avilla, E.; Galdiero, M.R.; Liotti, F.; Prevete, N.; Rossi, F.W.; Basolo, F.; Ugolini, C.; de Paulis, A.; et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 2010, 29, 6203–6215.
    7. Ammendola, M.; Sacco, R.; Donato, G.; Zuccala, V.; Russo, E.; Luposella, M.; Vescio, G.; Rizzuto, A.; Patruno, R.; De Sarro, G.; et al. Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology 2013, 85, 111–116.
    8. Malfettone, A.; Silvestris, N.; Saponaro, C.; Ranieri, G.; Russo, A.; Caruso, S.; Popescu, O.; Simone, G.; Paradiso, A.; Mangia, A. High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression. J. Cell. Mol. Med. 2013, 17, 1025–1037
    9. Michele Ammendola; Rosario Sacco; Giuseppe Sammarco; Giuseppe Donato; Severino Montemurro; Eustachio Ruggieri; Rosa Patruno; Ilaria Marech; Marica Cariello; Angelo Vacca; et al. Correlation between Serum Tryptase, Mast Cells Positive to Tryptase and Microvascular Density in Colo-Rectal Cancer Patients: Possible Biological-Clinical Significance. PLOS ONE 2014, 9, e99512, 10.1371/journal.pone.0099512.
    10. Li, G.; Yang, S.; Shen, P.; Wu, B.; Sun, T.; Sun, H.; Ji, F.; Zhou, D. SCF/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma. Am. J. Cancer Res. 2018, 8, 1064–1073.
    11. Marech, I.; Ammendola, M.; Gadaleta, C.; Zizzo, N.; Oakley, C.; Gadaleta, C.D.; Ranieri, G. Possible biological and translational significance of mast cells density in colorectal cancer. World J. Gastroenterol. 2014, 20, 8910–8920.
    12. Yu, Y.; Blokhuis, B.; Derks, Y.; Kumari, S.; Garssen, J.; Redegeld, F. Human mast cells promote colon cancer growth via bidirectional crosstalk: Studies in 2D and 3D coculture models. Oncoimmunology 2018, 7, e1504729.
    13. Lisa M. Coussens; Wilfred W. Raymond; Gabriele Bergers; Marion Laig-Webster; Ole Behrendtsen; Zena Werb; George H. Caughey; Douglas Hanahan; Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development 1999, 13, 1382-1397, 10.1101/gad.13.11.1382.
    14. Anca Maria Cimpean; Roberto Tamma; Simona Ruggieri; Beatrice Nico; Alina Toma; Domenico Ribatti; Mast cells in breast cancer angiogenesis. Critical Reviews in Oncology/Hematology 2017, 115, 23-26, 10.1016/j.critrevonc.2017.04.009.
    15. Judah Folkman; What Is the Evidence That Tumors Are Angiogenesis Dependent?. JNCI: Journal of the National Cancer Institute 1990, 82, 4-7, 10.1093/jnci/82.1.4.
    16. C. Jay Engel; Stefanie T. Bennett; Ann F. Chambers; Gordon S. Doig; Nancy Kerkvliet; Frances P. O'malley; Tumor Angiogenesis Predicts Recurrence in Invasive Colorectal Cancer When Controlled for Dukes Staging. American Journal of Surgical Pathology 1996, 20, 1260-1265, 10.1097/00000478-199610000-00012.
    17. Robert E. Frank; Theodore J. Saclarides; Sue Leurgans; Nicholas J. Speziale; Elizabeth A. Drab; David B. Rubin; Tumor Angiogenesis as a Predictor of Recurrence and Survival in Patients with Node-Negative Colon Cancer. Annals of Surgery 1995, 222, 695-699, 10.1097/00000658-199512000-00002.
    18. Detoraki, A.; Staiano, R.I.; Granata, F.; Giannattasio, G.; Prevete, N.; de Paulis, A.; Ribatti, D.; Genovese, A.; Triggiani, M.; Marone, G. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J. Allergy Clin. Immunol. 2009, 123, 1142–1149.
    19. Sammarco, G.; Varricchi, G.; Ferraro, V.; Ammendola, M.; De Fazio, M.; Altomare, D.F.; Luposella, M.; Maltese, L.; Currò, G.; Marone, G.; et al. Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. Int. J. Mol. Sci. 2019, 20, 2106.
    20. Xiangjie Guo; Liqin Zhai; Ruobing Xue; Jieru Shi; Qiang Zeng; Cairong Gao; Mast Cell Tryptase Contributes to Pancreatic Cancer Growth through Promoting Angiogenesis via Activation of Angiopoietin-1. International Journal of Molecular Sciences 2016, 17, 834, 10.3390/ijms17060834.
    21. V. Payne; P. C. A. Kam; Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004, 59, 695-703, 10.1111/j.1365-2044.2004.03757.x.
    22. Thomas Marichal; Mindy Tsai; Stephen J. Galli; Mast cells: potential positive and negative roles in tumor biology.. Cancer Immunology Research 2013, 1, 269-279, 10.1158/2326-6066.CIR-13-0119.
    23. Adams, W.J.; Morris, D.L. Short-course cimetidine and survival with colorectal cancer. Lancet 1994, 344, 1768–1769.
    24. Matsumoto, S. Cimetidine and survival with colorectal cancer. Lancet 1995, 346, 115.
    25. M. Gulubova; Tatyana Vlaykova; Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. Journal of Gastroenterology and Hepatology 2009, 24, 1265-1275, 10.1111/j.1440-1746.2007.05009.x.
    26. Michele Ammendola; Valeria Zuccalà; Rosa Patruno; Emilio Russo; Maria Luposella; Andrea Amorosi; Giuseppina Vescio; Giuseppe Sammarco; Severino Montemurro; Giovambattista De Sarro; et al. Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. Updates in Surgery 2012, 65, 53-57, 10.1007/s13304-012-0183-y.
    27. Patruno, R.; Marech, I.; Zizzo, N.; Ammendola, M.; Nardulli, P.; Gadaleta, C.; Introna, M.; Capriuolo, G.; Rubini, R.A.; Ribatti, D.; et al. c-Kit expression, angiogenesis, and grading in canine mast cell tumour: A unique model to study c-Kit driven human malignancies. BioMed. Res. Int. 2014, 2014, 730246.
    28. Ammendola, M.; Sacco, R.; Sammarco, G.; Luposella, M.; Patruno, R.; Gadaleta, C.D.; De Sarro, G.; Ranieri, G. Mast Cell-Targeted Strategies in Cancer Therapy. Transfus. Med. Hemother. 2016, 43, 109–113.